Publicaciones en las que colabora con Óscar María Beloqui Ruiz (50)

2020

  1. NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

2017

  1. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

2015

  1. Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis

    Free Radical Biology and Medicine, Vol. 86, pp. 352-361

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

  2. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis

    Journal of the American Heart Association, Vol. 3, Núm. 4

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

2012

  1. Two variants in the Fibulin2 gene are associated with lower systolic blood pressure and decreased risk of hypertension

    PLoS ONE, Vol. 7, Núm. 8

2011

  1. Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure

    Journal of Hypertension, Vol. 29, Núm. 5, pp. 876-883

  2. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: Role of NF-κB

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 31, Núm. 11, pp. 2733-2741

  3. Relación entre las fases precoces de la enfermedad renal y el síndrome metabólico

    Revista Espanola de Cardiologia, Vol. 64, Núm. 5, pp. 373-378

  4. The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes

    Frontiers in Bioscience - Elite, Vol. 3 E, Núm. 4, pp. 1467-1474

  5. ¿el síndrome metabólico en España necesita más estudios descriptivos o más evidencia de su implicación en prevención secundaria? Respuesta

    Revista Espanola de Cardiologia

2010

  1. Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]

    FEBS Letters

  2. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications

    Journal of Hypertension, Vol. 28, Núm. 9, pp. 1944-1950

  3. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein Kinase C: Potential clinical implications in hypertension (Hypertension (2009) 54 (744-750))

    Hypertension

  4. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2219-2226

  5. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease

    Kidney International, Vol. 78, Núm. 12, pp. 1275-1280

  6. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension (Clinical Science (2009) 116, (233-240))

    Clinical Science

2009

  1. Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients

    Journal of Hypertension, Vol. 27, Núm. 7, pp. 1420-1430

  2. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension

    Hypertension, Vol. 54, Núm. 4, pp. 744-750